Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Pfizer Corporation Hong Kong Limited - Transforming care in ER+ HER2- metastatic breast cancer with a focus on CDK4/6 inhibition

Optimizing management of ER+ HER2- mBC through Clinical & Real World Evidence

Date

19 Nov 2021

Session

Pfizer Corporation Hong Kong Limited - Transforming care in ER+ HER2- metastatic breast cancer with a focus on CDK4/6 inhibition

Presenters

Reshma Mahtani

Authors

R. Mahtani

Author affiliations

  • Medical Oncology Department, University of Miami, Sylvester Comprehensive Cancer Center, 33442 - Deerfield Beach/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.